Gene Yau
About Gene Yau
Gene Yau serves as the Executive Director of Corporate Development & Strategy at Nimbus Therapeutics, where he has worked since 2023. He has extensive experience in corporate development and strategy, having previously held senior roles at Nimbus Therapeutics, Astellas Pharma, and other notable companies.
Current Role at Nimbus Therapeutics
Gene Yau serves as the Executive Director of Corporate Development & Strategy at Nimbus Therapeutics. He has held this position since 2023, working on-site in Boston, Massachusetts. In this role, he is responsible for overseeing corporate development initiatives and strategic planning within the organization.
Previous Positions at Nimbus Therapeutics
Prior to his current role, Gene Yau worked at Nimbus Therapeutics in various capacities. He was the Sr. Director of Corporate Development & Strategy from 2021 to 2023 and the Director of Business Development from 2020 to 2021. His tenure at Nimbus included significant contributions to corporate strategy and business development efforts.
Educational Background
Gene Yau holds a Bachelor of Science (B.S.) in Biochemistry from the University of Illinois Urbana-Champaign, where he studied from 1993 to 1997. He also earned a Master of Science (M.S.) in Biotechnology from Northwestern University in 2000. Additionally, he obtained an MBA with a focus on Entrepreneurship and Finance from The University of Chicago Booth School of Business, completing his studies in 2006.
Professional Experience in Corporate Development
Gene Yau has extensive experience in corporate development across various organizations. He worked at Astellas Pharma as Associate Director of Corporate Development from 2013 to 2017. He also held the position of Director of Business Development at Blueprint Medicines from 2019 to 2020. His experience includes leading significant transactions and strategic initiatives in the pharmaceutical industry.
Achievements in Business Transactions
Gene Yau has played a key role in several high-profile business transactions. He contributed to the strategic entry of hematology and oncology pipelines into the Japanese market. He was instrumental in a $6 billion M&A transaction involving the TYK2 subsidiary to Takeda, which included $4 billion in cash. Additionally, he has led 15 deals with a combined value exceeding $10 billion.